Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, No. 1, East Jian She Road, Zhengzhou, 450052, Henan Province, People's Republic of China.
Department of Ultrasound, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, People's Republic of China.
Acad Radiol. 2020 May;27(5):704-709. doi: 10.1016/j.acra.2019.07.003. Epub 2019 Jul 31.
The goal of this study was to determine the clinical efficacy and safety of drug-eluting bead (DEB) transarterial chemoembolization (TACE) in combination with apatinib administration in patients with advanced hepatocellular carcinoma (HCC).
From December 2015 to May 2017, a total of 32 patients with advanced HCC treated with DEB-TACE combined with apatinib were consecutively enrolled in this study. The treatment response and laboratory outcomes were assessed at the first- and third month after DEB-TACE therapy. Overall survival, progression-free survival, and adverse events were also analyzed and assessed.
The objective response rate and disease control rate were 62.5% and 96.9% at the first month after treatment, respectively. At the third month after the first therapy, a slightly higher objective response rate (68.8%) and lower disease control rate (90.6%) were achieved. There were no differences in the levels of aspartate aminotransferase, alanine aminotransferase, serum albumin, or total bilirubin at M1 or M3 compared to M0 (all p> 0.05) The median progression-free survival was 9.5 months (95% confidence interval, 8.1-10.9 months), and the median overall survival was 22.0 months (95% confidence interval, 20.2-23.9 months). Among the 32 patients, 2 had hypertension and 1 had grade 3 diarrhea; the rest of the patients had mild to moderate adverse reactions that were acceptable, and no serious adverse reactions occurred.
DEB-TACE combined with apatinib is a safe and promising treatment approach for patients with advanced HCC.
本研究旨在评估载药微球（DEB）经动脉化疗栓塞（TACE）联合阿帕替尼治疗晚期肝细胞癌（HCC）的临床疗效和安全性。
2015 年 12 月至 2017 年 5 月，连续纳入 32 例接受 DEB-TACE 联合阿帕替尼治疗的晚期 HCC 患者。于 DEB-TACE 治疗后 1 个月和 3 个月评估治疗反应和实验室结果。分析并评估总生存期、无进展生存期和不良事件。
治疗后 1 个月的客观缓解率和疾病控制率分别为 62.5%和 96.9%。第 1 次治疗后 3 个月，客观缓解率（68.8%）略有升高，疾病控制率（90.6%）略有下降。与基线相比，1 个月和 3 个月时天门冬氨酸氨基转移酶、丙氨酸氨基转移酶、血清白蛋白和总胆红素水平均无差异（均 P>0.05）。中位无进展生存期为 9.5 个月（95%置信区间，8.1-10.9 个月），中位总生存期为 22.0 个月（95%置信区间，20.2-23.9 个月）。32 例患者中，2 例出现高血压，1 例出现 3 级腹泻；其余患者均出现轻至中度不良反应，可接受，未发生严重不良反应。
DEB-TACE 联合阿帕替尼是治疗晚期 HCC 安全且有前景的方法。
